<DOC>
	<DOCNO>NCT00001387</DOCNO>
	<brief_summary>The objective trial determine maximum tolerate dose toxicity paclitaxel give short hour infusion child refractory malignancy .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Trial Paclitaxel ( Taxol ) Given 3-Hour Infusion Pediatric Patients With Refractory Malignancy</brief_title>
	<detailed_description>Paclitaxel active antitumor agent demonstrate broad range activity preclinical clinical study . The optimal dose schedule yet determine either adults child . The objective trial determine maximum tolerate dose toxicity paclitaxel give short hour infusion child refractory malignancy . In addition , pharmacokinetics paclitaxel give way study model-dependent model-independent parameter determine .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer ( include leukemia ) : Refractory standard therapy ( objective disease progression require ) OR For standard therapy exist patient ineligible potentially curative surgery . PRIOR/CONCURRENT THERAPY : Recovery toxic effect prior therapy require . Biologic Therapy : Not specify . Chemotherapy : No prior taxanes . At least 3 week since myelosuppressive therapy ( 6 week since nitrosourea ) . Endocrine Therapy : Not specify . Radiotherapy : Prior extensive craniospinal pelvic irradiation allow . Surgery : Ineligible potential curative surgery . Other : Prior bone marrow transplant allow . PATIENT CHARACTERISTICS : Age : Over 1 21 ; Performance status : ECOG 02 ; Life expectancy : At least 8 week . Hematopoietic : ( except leukemia , bone marrow involvement , history bone marrow transplantation , extensive prior radiotherapy ) . Absolute granulocyte count least 1,500/mm ( 3 ) ; Platelet count least 100,000/mm ( 3 ) ; Hemoglobin least 8.0 g/dL . Hepatic : Bilirubin great 1.5 mg/dL ; AST less 2 time normal . Renal : Creatinine great 1.5 mg/dL OR ; Creatinine clearance least 60 mL/min per square meter . OTHER : No concurrent anticonvulsant therapy . No grade 2 bad neuropathy . No significant systemic illness ( e.g. , infection ) could compromise drug excretion confuse assessment toxicity . Not pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>Toxicity</keyword>
</DOC>